| MSOT in Pompe Disease (NCT05083806) | University of Erlangen-Nürnberg Medical School | 2022-05-17 |
| Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease (NCT05272969) | LMU Klinikum | 2022-03-31 |
| Carbon-13 Magnetic Resonance Spectroscopy in Glycogen Storage Diseases (NCT04929002) | Rigshospitalet, Denmark | 2021-12-10 |
| Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders (NCT04907162) | LMU Klinikum | 2021-04-15 |
| Gene Transfer Study in Patients With Late Onset Pompe Disease (NCT04174105) | Astellas Gene Therapies | 2020-10-27 |
| A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE) (NCT04093349) | Spark Therapeutics, Inc. | 2020-10-01 |
| ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD (NCT03911505) | Amicus Therapeutics | 2020-02-13 |
| A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD) (NCT04138277) | Amicus Therapeutics | 2019-12-18 |
| Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease (NCT03893240) | Spark Therapeutics, Inc. | 2019-06-12 |
| Study Determining the Frequency of Duchenne Muscular Dystrophy and Late-onset Pompe Disease (NCT04120168) | Turkish Society of Pediatric Gastroenterology, Hepatology and Nutrition | 2019-04-01 |
| Developing a Management Approach for Patients With "Late-Onset" Pompe Disease (NCT03694561) | Duke University | 2019-03-25 |
| A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease (NCT03729362) | Amicus Therapeutics | 2018-12-04 |
| Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa (NCT01288027) | Genzyme, a Sanofi Company | 2011-06-01 |
| Pompe Pregnancy Sub-Registry (NCT00567073) | Genzyme, a Sanofi Company | 2007-06-18 |
| Late-Onset Treatment Study Extension Protocol (NCT00455195) | Genzyme, a Sanofi Company | 2007-03-01 |
| Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support (NCT00268944) | Genzyme, a Sanofi Company | 2005-12-01 |
| A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease (NCT00158600) | Genzyme, a Sanofi Company | 2005-09-01 |
| A Study of rhGAA in Patients With Late-Onset Pompe Disease (NCT00250939) | Genzyme, a Sanofi Company | 2005-02-01 |
| Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies. (NCT00765414) | Genzyme, a Sanofi Company | 2003-04-01 |
| Alglucosidase Alfa Temporary Access Program (NCT00520143) | Genzyme, a Sanofi Company | |